XORTX Therapeutics Inc.
Index- P/E- EPS (ttm)-0.44 Insider Own4.36% Shs Outstand12.99M Perf Week-7.64%
Market Cap22.26M Forward P/E- EPS next Y-1.06 Insider Trans0.00% Shs Float12.42M Perf Month0.00%
Income-2.90M PEG- EPS next Q-0.24 Inst Own8.34% Short Float0.10% Perf Quarter-30.73%
Sales- P/S- EPS this Y13.00% Inst Trans- Short Ratio0.10 Perf Half Y-35.12%
Book/sh1.03 P/B1.29 EPS next Y- ROA-20.90% Target Price- Perf Year-7.60%
Cash/sh- P/C- EPS next 5Y- ROE-39.70% 52W Range1.11 - 8.19 Perf YTD-35.12%
Dividend- P/FCF- EPS past 5Y10.90% ROI- 52W High-83.75% Beta0.50
Dividend %- Quick Ratio19.40 Sales past 5Y- Gross Margin- 52W Low19.82% ATR0.19
Employees- Current Ratio19.40 Sales Q/Q- Oper. Margin- RSI (14)45.97 Volatility15.80% 14.17%
OptionableNo Debt/Eq0.00 EPS Q/Q0.20% Profit Margin- Rel Volume0.05 Prev Close1.35
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume117.24K Price1.33
Recom- SMA20-6.34% SMA50-9.18% SMA200-39.11% Volume5,236 Change-1.48%
Jun-21-22 07:00AM  
Jun-13-22 08:55AM  
Jun-08-22 07:00AM  
Jun-06-22 07:00AM  
May-25-22 08:00AM  
May-05-22 07:00AM  
May-03-22 07:00AM  
Apr-20-22 07:00AM  
Apr-12-22 07:00AM  
Apr-07-22 07:00AM  
Mar-31-22 07:00AM  
Mar-23-22 07:00AM  
Mar-14-22 07:00AM  
Jan-31-22 07:00AM  
Jan-20-22 07:00AM  
Jan-12-22 08:30AM  
Jan-10-22 07:00AM  
Dec-22-21 08:30AM  
Dec-21-21 06:00PM  
Dec-10-21 07:01AM  
Dec-09-21 11:53AM  
Dec-02-21 07:00AM  
Nov-23-21 07:00AM  
Nov-15-21 08:00AM  
Nov-09-21 07:00AM  
Nov-05-21 08:11AM  
Nov-04-21 02:49PM  
Nov-02-21 06:13PM  
Oct-15-21 05:38PM  
Oct-14-21 05:30PM  
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.